We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics


BD Diagnostics manufactures and markets medical supplies and devices and diagnostic systems that include cellular ana... read more Featured Products: More products

Download Mobile App

BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing

By LabMedica International staff writers
Posted on 31 Jan 2024
Print article
Image: The digital cervical cytology system scans samples and converts it to a digital slide image for reviewing on a computer (Photo courtesy of BD)
Image: The digital cervical cytology system scans samples and converts it to a digital slide image for reviewing on a computer (Photo courtesy of BD)

Cervical cancer is a global health concern, responsible for over 340,000 deaths among women each year. Ranking as the fourth most common cancer in women, its mortality rate can be significantly reduced with comprehensive screening strategies. While healthcare guidance is increasingly favoring HPV screening as the primary method for cervical cancer detection, Pap tests, or Pap smears, remain crucial. They are essential during the transition to HPV screening as the standard of care and for examining precancerous conditions and cancer following the detection of high-risk HPV infections. About one in 10 HPV tests yield positive results, which are then followed up with a Pap test for a visual examination of the cells.

Traditionally, Pap tests have involved collecting a sample from the patient, placing it on a glass slide, and having it examined under a microscope by a cytotechnologist or pathologist. Now, a new strategic collaboration aims to offer an AI-based algorithm to assist cytologists and pathologists in efficiently and effectively identifying signs of cervical cancer and precancer through whole-slide imaging. BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and Techcyte (Orem, UT, USA) have entered into an agreement that will allow BD to provide a comprehensive solution aimed at minimizing human error and increasing throughput. This will help laboratories enhance the standardization, reproducibility, and efficiency of Pap test results.

With the digital cervical cytology system, the samples can be scanned, converted to a digital slide image, and then reviewed on a computer monitor in a lab or from a remote location. In addition, the digital cervical cytology system uses an AI-based algorithm to prioritize and present clinically relevant cells for visual evaluation. The Techcyte platform is compatible with the most common liquid based cytology (LBC) preparations, including BD SurePath Liquid-based Pap Test vial and aims to be compatible with several of the most-used whole-slide imagers on the market. The Techcyte system is CE-marked per the IVD directive (98/79/EC) for clinical use in Europe, and Techcyte intends to seek full U.S. FDA approval for clinical use and CE certification to the IVDR (EU)2017/746. The BD and Techcyte IVDD solution will be commercially available in Europe in the first half of 2024, and in the U.S. subject to FDA approval for clinical use.

"There is a shortage of health care laboratory technicians, and the problem is particularly acute in the area of cytology" said Nikos Pavlidis, acting president of Diagnostic Solutions at BD. "This solution helps solve for the dearth of expert cytologists by leveraging new AI-based digital technology to make the testing process efficient and bring the traditional Pap test into the 21st century."

"Eye strain, fatigue, distractions, and intense workloads can make manually reading Pap smears difficult," added Ben Cahoon, CEO of Techcyte. "Our digital workflow supported by an AI-based algorithm can assist lab professionals in delivering consistent results for their patients. Our system presents the most diagnostically relevant cell images to guide the cytotechnologists and pathologists for efficient review and better decision making."

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rickettsia Conorii Assay

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.